Source-grounded facts extracted from Pulmonx Corp's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Pulmonx Corp shareholders approved Non-Binding Advisory Vote to Approve the Company’s Executive Compensation at the 2026-06-04 meeting.
“Proposal 3 – Non-Binding Advisory Vote to Approve the Company’s Executive Compensation The stockholders approved, on a non-binding advisory basis, the Company’s executive compensation as disclosed in the Proxy Statement. The voting results were as follows: For Against Abstain Broker Non-Votes 17,196,362 3,485,784 132,764 11,830,360”
Pulmonx Corp shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2026-06-04 meeting.
“Proposal 2 – Ratification of Appointment of Independent Registered Public Accounting Firm The stockholders ratified the appointment of BDO USA, P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The voting results were as follows: For Against Abstain 31,458,698 97,509 1,089,063 There were no broker non-votes with respect to Proposal 2.”
Pulmonx Corp shareholders approved Election of three Class III directors at the 2026-06-04 meeting.
“Proposal 1 – Election of Directors The stockholders elected each of the three nominees for Class III director to serve until the Company’s 2029 Annual Meeting of Stockholders and until their successor has been elected and qualified. The voting results were as follows: For Withheld Broker Non-Votes Thomas W. Burns 19,751,638 1,063,272 11,830,360 Georgia Garinois-Melenikiotou 17,680,826 3,134,084 11,830,360 Dana G. Mead, Jr. 19,853,196 961,714 11,830,360”
Pulmonx Corp reported the first quarter of 2026 ended March 31, 2026 results: revenue $20.6 million, net income Net loss in the first quarter of 2026 was $13.7 million, EPS $0.33 per share. Guidance reaffirmed.
“invasive treatments for lung disease, today reported financial results for the first quarter of 2026 ended March 31, 2026. Recent Highlights • Achieved worldwide revenue of $20.6 million in the first quarter of 2026, a 9% decrease over the same period last year and a decrease of 12% on a constant currency basis • Delivered $13.3 million in U.S. revenue in the”
Pulmonx Corp issued 1,000,000 shares of warrant to Perceptive Credit Holdings V, LP.
“On the Closing Date, the Company issued to Perceptive a warrant to purchase up to 1,000,000 shares of the Company’s common stock, par value $0.001 per share, with an exercise price of $1.92 per share”
Pulmonx Corp incurred term loan of up to $60.0 million with Perceptive Credit Holdings V, LP at 7.00% plus the greater of one-month term SOFR and 3.75% maturing March 2, 2031.
“a senior secured term loan facility in an aggregate principal amount of up to $60.0 million”
Pulmonx Corp entered into Credit Agreement and Guaranty with Perceptive Credit Holdings V, LP valued at up to $60.0 million (effective 2026-03-02).
“On March 2, 2026 (the “Closing Date”), Pulmonx Corporation (the “Company”) entered into a Credit Agreement and Guaranty (the “Credit Agreement”) and a Security Agreement (the “Security Agreement”), with Perceptive Credit Holdings V, LP (“Perceptive”), as the initial lender, administrative agent and collateral agent. The Perceptive Credit Agreement provides for a senior secured term loan facility in an aggregate principal amount of up to $60.0 million (the “Loan Facility”).”
Pulmonx Corp shareholders approved Non-Binding Advisory Vote to Approve the Company's Executive Compensation at the 2024-05-16 meeting.
“Proposal 3 – Non-Binding Advisory Vote to Approve the Company’s Executive Compensation The stockholders approved, on a non-binding advisory basis, the Company’s executive compensation as disclosed in the Proxy Statement. The voting results were as follows: For Against Abstain Broker Non-Votes 16,307,204 14,268,198 8,722 3,802,601”
Pulmonx Corp shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2024-05-16 meeting.
“Proposal 2 – Ratification of Appointment of Independent Registered Public Accounting Firm The stockholders ratified the appointment of BDO USA, P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024. The voting results were as follows: For Against Abstain 34,338,117 38,937 9,671”
Pulmonx Corp shareholders approved Election of Class I directors at the 2024-05-16 meeting.
“Proposal 1 – Election of Directors The stockholders elected each of the two nominees for Class I director to serve until the Company’s 2027 Annual Meeting of Stockholders and until their successor has been elected and qualified. The voting results were as follows: For Withheld Broker Non-Votes Glendon E. French 16,898,796 13,685,328 3,802,601 Tiffany Sullivan 16,725,724 13,858,350 3,802,601”
Mehul Joshi was appointed as Chief Financial Officer and Principal Financial and Accounting Officer at Pulmonx Corp.
“On March 19, 2024, the board of directors of Pulmonx Corporation (the “Company”) appointed Mehul Joshi as the Company’s Chief Financial Officer and Principal Financial and Accounting Officer, effective upon commencement of his employment with the Company on April 3, 2024 (the “Effective Date”).”
Pulmonx Corp reported full year 2024 results: revenue $81 million to $84 million. Guidance initiated.
“Pulmonx expects revenue for the full year 2024 to be in the range of $81 million to $84 million.”
Pulmonx Corp reported full year ended December 31, 2023 results: revenue $68.7 million, net income $60.8 million net loss, EPS -$1.60 per share.
“Total worldwide revenue for the full year of 2023 was $68.7 million, a 28% increase from $53.7 million for the full year of 2022 and an increase of 28% on a constant currency basis.”
Pulmonx Corp reported fourth quarter ended December 31, 2023 results: revenue $19.3 million, net income $13.9 million net loss, EPS -$0.36 per share.
“Total worldwide revenue in the fourth quarter of 2023 was $19.3 million, a 25% increase from $15.4 million in the fourth quarter of 2022 and an increase of 23% on a constant currency basis.”
Steven S. Williamson was appointed as President and Chief Executive Officer at Pulmonx Corp.
“On February 19, 2024, the Company’s board of directors appointed Steven S. Williamson as the Company’s President and Chief Executive Officer and a Class II member of the board of directors, each as of the Effective Date.”
Glendon E. French resigned as President and Chief Executive Officer at Pulmonx Corp.
“On February 20, 2024, Glendon E. French resigned as President and Chief Executive Officer of Pulmonx Corporation (the “Company”), effective as of March 15, 2024”
Pulmonx Corp reported the third quarter of 2023 ended September 30, 2023 results: revenue $17.7 million, net income $14.9 million, EPS $0.39 per share. Guidance raised.
“Total worldwide revenue in the third quarter of 2023 was $17.7 million”
Pulmonx Corp reported third quarter 2023 results: revenue approximately $17.6 million.
“Preliminary, unaudited third quarter 2023 revenue expected to be approximately $17.6 million”
John McKune was appointed as Interim Chief Financial Officer at Pulmonx Corp.
“John McKune, Vice President, Corporate Controller of the Company, was appointed by the Board of Directors of the Company (the “ Board ”) to serve as the Interim Chief Financial Officer of the Company, effective as of the Effective Date.”
Derrick Sung resigned as Chief Financial Officer at Pulmonx Corp.
“On October 6, 2023, Derrick Sung, Ph.D., Chief Financial Officer of the Company, stepped down from his position, effective October 10, 2023 (the “ Effective Date ”), to pursue a new business opportunity.”
Pulmonx Corp reported second quarter of 2023 ended June 30, 2023 results: revenue $17.2 million, net income $16.2 million, EPS $0.43 per share. Guidance raised.
“treatments for lung disease, today reported financial results for the second quarter of 2023 ended June 30, 2023. Recent Highlights • Achieved record worldwide revenue of $17.2 million in the second quarter of 2023, a 23% increase over the same period last year • Delivered a new high of $11.0 million in U.S. revenue in the second quarter of 2023, representing”
Pulmonx Corp shareholders rejected Non-Binding Advisory Vote to Approve the Company’s Executive Compensation at the 2023-05-17 meeting.
“The resolution to approve, on a non-binding advisory basis, the Company’s executive compensation as disclosed in the Proxy Statement did not pass.”
Pulmonx Corp shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2023-05-17 meeting.
“The stockholders ratified the appointment of BDO USA, LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.”
Pulmonx Corp shareholders approved Election of Directors at the 2023-05-17 meeting.
“The stockholders elected each of the three nominees for Class III director to serve until the Company’s 2026 Annual Meeting of Stockholders and until their successor has been elected and qualified.”
Pulmonx Corp reported first quarter of 2023 ended March 31, 2023 results: revenue $14.5 million, EPS $0.42 per share. Guidance reaffirmed.
“invasive treatments for lung disease, today reported financial results for the first quarter of 2023 ended March 31, 2023. Recent Highlights • Recorded worldwide revenue of $14.5 million in the first quarter of 2023, a 35% increase over the same period last year and an increase of 37% on a constant currency basis • Delivered $9.3 million in U.S. revenue in the”
Pulmonx Corp reported the full year 2023 results: revenue $63 million to $65 million. Guidance initiated.
“Pulmonx expects revenue for the full year 2023 to be in the range of $63 million to $65 million.”
Pulmonx Corp reported the full year of 2022 results: revenue $53.7 million, net income $58.9 million, EPS $1.59 per share.
“invasive treatments for lung disease, today reported financial results for the fourth quarter and full year of 2022 ended December 31, 2022. Recent Highlights • Delivered $53.7 million in worldwide revenue for the full year of 2022 • Achieved record worldwide revenue of $15.4 million for the fourth quarter of 2022, a 13% increase over the same period last year”
Pulmonx Corp reported the fourth quarter of 2022 results: revenue $15.4 million, net income $14.3 million, EPS $0.38 per share.
“and full year of 2022 ended December 31, 2022. Recent Highlights • Delivered $53.7 million in worldwide revenue for the full year of 2022 • Achieved record worldwide revenue of $15.4 million for the fourth quarter of 2022, a 13% increase over the same period last year and an increase of 18% in constant currency • Set a new record of $32.5 million and $9.5 million in”
Pulmonx Corp incurred credit facility of $20.0 million with Canadian Imperial Bank of Commerce at 1.0% above the Wall Street Journal Prime Rate.
“On February 21, 2023, the Company exercised its option to draw $20.0 million available under a Loan and Security Agreement with Canadian Imperial Bank of Commerce (“CIBC”).”
Pulmonx Corp reported full year 2022 results: revenue 51.5 million to 52.5 million. Guidance lowered.
“Pulmonx is updating its full year 2022 revenue guidance to be in the range of $51.5 million to $52.5 million, as compared to previously communicated guidance of $55 million to $60 million.”
Pulmonx Corp reported third quarter ended September 30, 2022 results: revenue 13.5 million.
“invasive treatments for lung disease, today reported financial results for the third quarter ended September 30, 2022. Recent Highlights • Achieved worldwide revenue of $13.5 million in the third quarter of 2022, a 2% increase over the same period last year and an increase of 7% on a constant currency basis, driven by U.S. revenue of $8.4 million representing”
Pulmonx Corp amended Third Amendment to Amended and Restated Loan and Security Agreement with Canadian Imperial Bank of Commerce valued at $20,000,000 (effective 2022-10-31).
“On October 31, 2022, the Company executed a Third Amendment to Amended and Restated Loan and Security Agreement (the “Third Amendment”) with Canadian Imperial Bank of Commerce (“CIBC”), which amended certain provisions of the Company’s existing Amended and Restated Loan and Security Agreement, dated as of March 29, 2021”
Tiffany Sullivan was appointed as Class I Director at Pulmonx Corp.
“Effective as of July 29, 2021, the Company’s Board of Directors (the “Board”) appointed Ms. Alissa Hsu Lynch and Ms. Tiffany Sullivan and to serve as Class I directors of the Board.”
Alissa Hsu Lynch was appointed as Class I Director at Pulmonx Corp.
“Effective as of July 29, 2021, the Company’s Board of Directors (the “Board”) appointed Ms. Alissa Hsu Lynch and Ms. Tiffany Sullivan and to serve as Class I directors of the Board.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.